Drugs / INO-6145
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03606213 Comparator | Aug 2018 → May 2021 | HIV infectious disease | Steven Deeks | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-6145 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03606213 ↗ |
| Route | Other | “Active gag/pol and IL-12 plasmids (INO-6145 INO-9012) will be administered by electroporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.” NCT03606213 ↗ |